The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Jens, Köhler, Natalie, Maringer, Yacine, Bucher, Philip, Bilich, Tatjana, Zwick, Melissa, Dicks, Severin, Nelde, Annika, Dubbelaar, Marissa, Scheid, Jonas, Wacker, Marcel, Heitmann, Jonas S., Schroeder, Sarah, Rieth, Jonas, Denk, Monika, Richter, Marion, Klein, Reinhild, Bonzheim, Irina, Luibrand, Julia, Holzer, Ursula, Ebinger, Martin, Brecht, Ines B., Bitzer, Michael, Boerries, Melanie, Feucht, Judith, Salih, Helmut R., Rammensee, Hans-Georg, Hailfinger, Stephan, Walz, Juliane S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613889/
https://www.ncbi.nlm.nih.gov/pubmed/36302754
http://dx.doi.org/10.1038/s41467-022-33746-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613889/
https://www.ncbi.nlm.nih.gov/pubmed/36302754
http://dx.doi.org/10.1038/s41467-022-33746-3

Ejemplares similares